The Evolving Role of Orexin-Based Therapy in Narcolepsy Type 1 Management

Proprietary Educational Format:

Activity Overview

A debilitating, chronic disorder mediated by the irreversible loss of hypocretin/orexin (ORX) neurons, narcolepsy type 1 (NT1) is often misdiagnosed or underdiagnosed. Moreover, while there are a number of available therapies for NT1, many are associated with adverse effects and are symptomatic. However, novel agents that target the pathophysiology of NT1 have demonstrated efficacy and safety profiles in recent studies.

Join our expert faculty for this virtual Care Team Forum℠ symposium, featuring a series of panel discussions on recognition, pathophysiology, and treatment of NT1. Each panel topic will be augmented by the perspectives of an experienced patient with NT1, who will share valuable teaching moments from their therapeutic journey.

1.00 CE Credit(s)
Expires: October 29, 2021

Target Audience

This activity is intended for neurology and primary care clinicians involved in the treatment of narcolepsy type 1 (NT1).

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Recognize contemporary challenges in the management of NT1
  • Evaluate the role of orexin in the underlying pathophysiology of NT1
  • Analyze available data on emerging orexin-based therapies for the treatment of NT1
  • Identify patients with NT1 who might derive benefit from treatment with orexin-based therapy

Activity Faculty

Thorpy 300x400

Michael J. Thorpy, MD (Chair)

Professor, Neurology
Albert Einstein College of Medicine
Bronx, New York, United States​

Dauvilliers 300x400

Yves Dauvilliers, MD, PhD

Professor, Neurology and Physiology
Sleep Unit, Gui de Chauliac Hospital
University of Montpellier
Montpellier, France​

Scammell 300x400

​Thomas E. Scammell, MD

Professor, Neurology
Harvard Medical School
Beth Israel Deaconess Medical Center
Boston Children’s Hospital
Boston, Massachusetts, United States